JAMM Therapeutics
Systemic Lupus Erythematosus Treatment
Health Tech & Life Sciences
Non Active, Jul 2024 ceased to operate
Company Overview
Snapshot
Founded in October 2019, JAMM Therapeutics operated with 1–10 employees. The company secured one disclosed funding round from two investors, FutuRx and RMGP Biopharma Investment Fund, in May 2020.
Business overview
JAMM Therapeutics is a drug discovery company focused on developing a novel treatment approach for systemic lupus erythematosus. The company's core technology is centered on pharmaceutical research and development, operating within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development categories. It serves the healthcare and life sciences market, with a particular focus on pharmaceuticals.
Log in to access full profile ›Company Intelligence Q&A
- What is JAMM Therapeutics' primary focus?
- JAMM Therapeutics is a drug discovery company dedicated to developing a novel treatment for systemic lupus erythematosus.
- When was JAMM Therapeutics founded?
- JAMM Therapeutics was founded in October 2019.
- What was the company's operational status as of July 2024?
- As of July 2024, JAMM Therapeutics ceased to operate and is considered non-active.
- Which investors participated in JAMM Therapeutics' funding round?
- In May 2020, JAMM Therapeutics received funding from FutuRx and RMGP Biopharma Investment Fund.
- What sector does JAMM Therapeutics operate in?
- JAMM Therapeutics operates within the Health Tech & Life Sciences sector, with a specific focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.